by Rod Raynovich | Apr 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Sector Outperforming Within NASDAQ A torrid run-up of over 10% in biotech stocks over the past 3 weeks brings caution to mind as the NASDAQ sell-off hits 1%. Over the past 5 days the NASDAQ sell-off is 2% while biotech indices are only down 1%,...
by Rod Raynovich | Apr 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL $12.17) has hired Goldman-Sachs to deal with potential takeover bids according to stories in Reuters and Bloomberg. Exelixis has a Phase III cancer drug XL184 (cabozantinab) and announced positive Phase 2 interim data for prostate cancer on Feb. 17....
by Rod Raynovich | Apr 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biogen (BIIB $78.24) soared today on positive top line data on the Phase 3 Trial for oral BG-12 (dimethyl fumarate) as a montherapy in people with relapsing-remitting multiple sclerosis (RRMS). Results showed that 240 mg of BG-12 2x or 3x a day met the primary and...
by Rod Raynovich | Apr 8, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Reviewing Today’s Action A mixed market today with a slight edge to the bulls. Immunogen(IMGN $12.28) up 4% continues its run from yesterday on positive data from its collboration with Roche on T-DM1 (trastuzumab) an antibody coupled with a cell killing agent...
by Rod Raynovich | Apr 6, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, BIOgraph
11/29/11 No new buys on tools/Dx since summer meltdown and Illumina (ILMN) miss. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are up 1.6% as of mid-day. Mixed tape in Dx and Tools with winners BLUD,...
by Rod Raynovich | Apr 5, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Dr. Mark Monane Senior Analyst of Biotechnology at Needham & Co. was on CNBC today giving a turbo boost to the biotech rally that began in mid-March. 100 companies are presenting at the Conference. Over the past 3 weeks the biotech sector is up almost 10%. Two...
by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
11/18 Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF. 11/15/11 Comments: Under review: ImmunoGen (IMGN) Dropped FBT an ETF in favor of IBB or possibly XBI. For bullish equity allocation in Tech and Biotech use QQQ. 6/20/11 NASDAQ (2632) Market...
by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and admits Cubist patents are valid. Cubist Pharmaceuticals Settles CUBICIN...
by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Platform Technologies Are In Demand: M&A Driver Intact Exact Sciences (EXAS $7.50) continued to run today up 3% and 1.3 pts in five days on no apparent news except presentations at recent investment conferences. The Company is developing a molecular diagnostic...
by Rod Raynovich | Mar 31, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biopharmaceutical stocks caught bids today (in a weak technology market) after yesterday’s M&A spiked rally. Large cap leaders in the NASDAQ-100 were up: Biogen(BIIB) up 1.63%, Celgene (CELG) up 1.6% and Gilead (GILD) up 0.68%. Major ETF’s-IBB FBT XBI-...
